NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis → Altcoin FRENZY Alert… (From Crypto 101 Media) (Ad) Free TXMD Stock Alerts $2.30 -0.10 (-4.17%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.21▼$2.6150-Day Range$2.23▼$2.6952-Week Range$1.95▼$4.72Volume54,599 shsAverage Volume19,098 shsMarket Capitalization$24.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get TherapeuticsMD alerts: Email Address Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About TherapeuticsMD Stock (NASDAQ:TXMD)TherapeuticsMD, Inc. operates as a pharmaceutical company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY,BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More TXMD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TXMD Stock News HeadlinesMarch 15, 2024 | americanbankingnews.comShort Interest in TherapeuticsMD, Inc. (NASDAQ:TXMD) Declines By 18.8%March 14, 2024 | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.comMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 12, 2024 | msn.com25 Countries With Highest Abortion RatesMarch 10, 2024 | sg.finance.yahoo.comTherapeuticsMD, Inc. (TXMD) stock historical prices & data – Yahoo FinanceDecember 29, 2023 | morningstar.comTherapeuticsMD Inc TXMDNovember 15, 2023 | nasdaq.comDaily Markets: Today Brings Producer Prices, Retail Sales DataNovember 14, 2023 | marketwatch.comTherapeuticsMD to Consider Strategic AlternativesMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.November 14, 2023 | msn.comTherapeuticsMD exploring strategic alternatives for companyNovember 14, 2023 | finance.yahoo.comTherapeuticsMD Announces Third Quarter 2023 Financial ResultsOctober 4, 2023 | bizjournals.comBoca Raton-based prescription service announces layoffs, says a third of workforce could be cutSeptember 20, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Wednesday, underperforms marketAugust 15, 2023 | marketwatch.comTherapeuticsMD Inc. stock outperforms market despite losses on the dayAugust 14, 2023 | finance.yahoo.comTherapeuticsMD Announces Second Quarter 2023 Financial ResultsAugust 9, 2023 | finance.yahoo.comMicron Biomedical Appoints Brian Bernick, MD as Chairman of Its Board of DirectorsJuly 5, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Wednesday when compared to competitorsJuly 4, 2023 | thestreet.comTherapeuticsMD Rejected by FDA, Delay Could Be FatalMay 23, 2023 | seekingalpha.comTherapeuticsMD: From Fallen And Forgotten To Cash CowMay 15, 2023 | finance.yahoo.comTherapeuticsMD Announces First Quarter 2023 Financial ResultsMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Tuesday, underperforms marketMay 10, 2023 | marketwatch.comTherapeuticsMD Inc. stock rises Wednesday, still underperforms marketMay 3, 2023 | marketwatch.comTherapeuticsMD Inc. stock falls Monday, underperforms marketApril 30, 2023 | marketwatch.comTherapeuticsMD Inc. stock underperforms Friday when compared to competitorsApril 23, 2023 | marketwatch.comTherapeuticsMD Inc. stock outperforms market on strong trading dayApril 14, 2023 | msn.comAll You Need to Know About TherapeuticsMD (TXMD) Rating Upgrade to BuyApril 7, 2023 | finance.yahoo.comTherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model TransitionSee More Headlines Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2023Today3/18/2024Next Earnings (Estimated)4/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$112 million Net Margins47.29% Pretax Margin60.97% Return on Equity133.83% Return on Assets66.54% Debt Debt-to-Equity RatioN/A Current Ratio1.20 Quick Ratio1.20 Sales & Book Value Annual Sales$69.96 million Price / Sales0.35 Cash FlowN/A Price / Cash FlowN/A Book Value$3.73 per share Price / Book0.62Miscellaneous Outstanding Shares10,580,000Free Float10,453,000Market Cap$24.33 million OptionableOptionable Beta1.03 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesGovernor Thomas G. Thompson (Age 82)Executive Chairman Comp: $150kMr. Marlan D. Walker J.D. (Age 48)Chief Executive Officer Comp: $1.13MMr. Robert G. Finizio (Age 53)Co-Founder Comp: $7.51kMr. Michael C. Donegan (Age 56)Interim CFO & Chief Accounting Officer Comp: $712.59kMs. Daniella Silva (Age 38)Chief Compliance Officer Mr. Benjamin Foulk (Age 54)Vice President of Human Resources Mr. Bharat Warrier (Age 46)Chief Manufacturing Officer Mr. Douglas SteelmanVice President of Market AccessMs. Dedra LydenVice President of Strategic Partnerships & InitiativesMore ExecutivesKey CompetitorsCalciMedicaNASDAQ:CALCAileron TherapeuticsNASDAQ:ALRNSol-Gel TechnologiesNASDAQ:SLGLLisata TherapeuticsNASDAQ:LSTALumos PharmaNASDAQ:LUMOView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 7,100 shares on 2/15/2024Ownership: 0.000%ADAR1 Capital Management LLCBought 272,160 shares on 2/14/2024Ownership: 2.572%Marlan D WalkerSold 14,500 sharesTotal: $33,495.00 ($2.31/share)Marlan D WalkerSold 1,170 sharesTotal: $4,270.50 ($3.65/share)View All Insider TransactionsView All Institutional Transactions TXMD Stock Analysis - Frequently Asked Questions Should I buy or sell TherapeuticsMD stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares. View TXMD analyst ratings or view top-rated stocks. How have TXMD shares performed in 2024? TherapeuticsMD's stock was trading at $2.25 on January 1st, 2024. Since then, TXMD stock has increased by 2.2% and is now trading at $2.30. View the best growth stocks for 2024 here. Are investors shorting TherapeuticsMD? TherapeuticsMD saw a decline in short interest during the month of February. As of February 29th, there was short interest totaling 40,900 shares, a decline of 18.8% from the February 14th total of 50,400 shares. Based on an average trading volume of 22,400 shares, the short-interest ratio is currently 1.8 days. Currently, 0.4% of the shares of the stock are sold short. View TherapeuticsMD's Short Interest. When is TherapeuticsMD's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, April 5th 2024. View our TXMD earnings forecast. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its quarterly earnings data on Monday, August, 14th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.17. The firm had revenue of $0.44 million for the quarter. TherapeuticsMD had a net margin of 47.29% and a trailing twelve-month return on equity of 133.83%. When did TherapeuticsMD's stock split? Shares of TherapeuticsMD reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU). Who are TherapeuticsMD's major shareholders? TherapeuticsMD's stock is owned by many different retail and institutional investors. Top institutional shareholders include ADAR1 Capital Management LLC (2.57%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson. View institutional ownership trends. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TXMD) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.